Cefixime Acid, Thiazine Isomer Impurity, Disodium Salt

IMPURITIES

Product Details

CAT No.# CS-O-15248
Category Impurities
CAS 108615-31-2 (Free Acid)
Molecular Weight 537.41
Molecular Formula C16H14N5Na3O8S2
Purity: >98%
Synonyms: α-[[2-(2-Amino-4-thiazolyl)-2-[(carboxymethoxy)imino]acetyl]amino]-4-carboxy-5-ethylidene-5,6-dihydro-2H-1,3-thiazine-2-acetic Acid Sodium Salt; α-[[(2-Amino-4-thiazolyl)[(carboxymethoxy)imino]acetyl]amino]-4-carboxy-5-ethylidene-5,6-dihydro-2H-1,3-thiazine-2-acetic Acid Sodium Salt
Application Notes: Impurity in commercial preparation of Cefixime and an orally active third generation cephalosporin antibiotic.
References: Kamimura, T., et al.: Antimicrob. Agents Chemother., 25, 98 (1984); Yamanaka, H., et al.: J. Antibiot., 38, 1738 (1985); Guay, D.R.P., et al.: Antimicrob. Agents Chemother., 30, 485 (1986)
COA / MSDS:    View COA    MSDS    Enquire
The balance used are calibrated with weights traceable to National Standards NIST for accuracy
PEOPLE ALSO SEARCHED FOR: 1. (6R,7S)-7-(2-chloroacetamido)-7-methoxy-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
2. propan-2-yl-5-hydroxy-2-methyl-2-4-(3-nitrophenyl)-6-oxo-1,4,5,5-tetraahydropyridine-3-carboxylate
3. ([13C6]Leu5)-Ghrelin (human) (H-7252.1000)
4. Benidipine D7
5. Lauroside D
6. Triazolam 13C D3
7. Icatibant impurity 1
8. BISPHENOL AF (RING-13C12)
9. 0.1% TFA in Water ULC-MS
10. Metamizole EP Impurity C HCl
11. Silodosin Metabolite D4
12. Brivaracetam Carboxylic acid metabolite [UCB 42145]
13. Terbuthylazine D5
14. tibolone (848)
15. (Z)-Dimethylvinphos
16. Silodosin Metabolite
17. 2-Phenoxymethanesulfonanilide
18. Nimesulide EP Impurity A
19. Acetone HPLC
20. Nandrolone Decanoate EP impurity F


SMILES:
[O-]C(C(NC(/C(C1=CSC(N)=N1)=N/OCC([O-])=O)=O)C(N=C/2C([O-])=O)SCC2=C/C)=O.[Na+].[Na+].[Na+]



This page contains information about Cefixime Acid, Thiazine Isomer Impurity, Disodium Salt Cas 108615-31-2 (Free Acid) and its Impurities.
"Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk."